CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Checkpoint Surgical

Checkpoint Surgical advances the science and practice of nerve protection and repair to improve the quality of life for patients and physicians.

DUSA Pharmaceuticals

DUSA Pharmaceuticals is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Associates of Cape Cod

Associates of Cape Cod is a East Falmouth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nordic Naturals

Nordic Naturals is a Watsonville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nulixir

Nulixir is a B2B nanobiotechnology company that develops, manufactures, and licenses intellectual property for smart nanocarriers, called nanovesicles, which optimize the performance of functional ingredients in food & beverage products.